Shingles vaccines may reduce dementia risk, two large new studies ... - CNN
WEBJul 30, 2024 · CNN — Two new studies suggest that getting a vaccine to protect against a painful case of shingles may be beneficial for memory, too. An estimated 98% of US adults have had chickenpox and are at...
Evidence mounts that shingles vaccines protect against dementia
WEBJul 25, 2024 · Being immunised against shingles has been linked to a reduced dementia risk before and now a study suggests that the newer vaccine wards off the condition more effectively than an older one. By...
Two-dose shingles vaccine is still highly effective after four years
WEBApr 1, 2024 · The CDC recommends adults ages 50 and older get two doses of the recombinant zoster vaccine (Shingrix), with the doses separated by two to six months, to prevent shingles. But how long can it offer protection?
New shingles vaccine could reduce risk of dementia
WEBJul 25, 2024 · The new recombinant shingles vaccine ‘Shingrix’ is associated with a reduced risk of dementia compared to an earlier shingles vaccine, according to a major new study published in Nature Medicine. It is also …
New Shingles Vaccine FAQ | Shingrix - Consumer Reports
WEBJan 25, 2018 · Today, the Centers for Disease Control and Prevention made its formal recommendations for the use of Shingrix —a new vaccine that appears to offer significantly better protection against...
GSK Announces Positive Topline Data on Co-Administration of …
WEB4 days ago · Indication for SHINGRIX SHINGRIX is an FDA-approved vaccine for the prevention of shingles (herpes zoster) in: Adults 50 years and older. Adults 18 years and older who are or will be at increased ...
Shingles Vaccine Recommendations | Shingles (Herpes Zoster) | CDC
WEBJul 19, 2024 · CDC recommends Shingrix (recombinant zoster vaccine or RZV) for the prevention of herpes zoster (shingles) and related complications. This page summarizes CDC's current shingles vaccine recommendations.
New long-term data show SHINGRIX continues to provide high
WEBApr 17, 2024 · GSK plc (LSE/NYSE: GSK) today announced positive data from the ZOSTER-049 long-term follow-up phase III trial which followed participants for up to approximately 11 years following initial vaccination with SHINGRIX (Recombinant Zoster Vaccine or RZV).
Pfizer and BioNTech Initiate Phase 1/2 Study of First mRNA-based ...
WEBFeb 10, 2023 · NEW YORK and MAINZ, GERMANY, FEBRUARY 10, 2023 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the start of a Phase 1/2 trial exploring the safety, tolerability, and immunogenicity of the companies’ mRNA vaccine candidates against shingles (also known as herpes zoster, or HZ), a debilitating disease caused by the varicel...
Shingles Vaccination | Shingles (Herpes Zoster) | CDC
WEBJul 19, 2024 · Shingles vaccination is the only way to protect against shingles and related complications from the disease. The vaccine is given as a two-dose series. What's available. Recombinant zoster (shingles) vaccine called Shingrix can prevent shingles. Shingles vaccine may be given at the same time as other vaccines.
- Some results have been removed